Loading clinical trials...

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 3NCT01429441

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

The purpose of this study is to evaluate the treatment of symptomatic vitreomacular adhesion / (VMT) including macular hole with ocriplasmin.

Lead sponsor: ThromboGenics•25 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment220

Start dateOct 2011

Last updatedMar 14, 2016

Condition

Vitreomacular Adhesion Including Macular Hole

Locations shown

Retinal Consultants of Arizona

Phoenix, Arizona

Retina-Vitreous Associates Medical Group

Beverly Hills, California

Retina Consultants Medical Group

Sacramento, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 14, 2016Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions